Advertisement
Screener

Freenome, Inc. (FRNM) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Freenome, Inc. Operating Cash Flow

Freenome, Inc. (FRNM) reported Operating Cash Flow of -$427.66 thousand for the 6-month period ending 2026-06-30, per its S-1 filed 2026-08-18.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-18

  • Freenome, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$129.81K.
  • Freenome, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$297.85K.
  • Freenome, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$312.88K.
  • Freenome, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$166.50K.
Period endNet Cash Provided by (Used in) Operating Activities 0 monthNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$129.81K
derived: S-1 6 month − S-4/A 3 month · filed 2026-08-18
-$427.66K
S-1 · filed 2026-08-18
-$740.54K
derived: sum of 3 quarters · filed 2026-08-18
-$907.04K
derived: sum of 4 quarters · filed 2026-08-18
2026-03-31-$297.85K
S-4/A · filed 2026-06-11
-$610.73K
derived: sum of 2 quarters · filed 2026-08-18
-$777.23K
derived: sum of 3 quarters · filed 2026-08-18
-$924.76K
derived: sum of 4 quarters · filed 2026-08-18
2025-12-31-$312.88K
derived: S-1 12 month − 10-Q 9 month · filed 2026-08-18
-$479.38K
derived: sum of 2 quarters · filed 2026-08-18
-$626.91K
derived: sum of 3 quarters · filed 2026-08-18
-$864.65K
S-1 · filed 2026-08-18
2025-09-30-$166.50K
derived: 10-Q 9 month − S-1 6 month · filed 2025-11-13
-$314.03K
derived: sum of 2 quarters · filed 2026-08-18
-$551.77K
10-Q · filed 2025-11-13
-$631.54K
derived: sum of 4 quarters · filed 2026-08-18
2025-06-30-$147.53K
derived: S-1 6 month − S-4/A 3 month · filed 2026-08-18
-$385.27K
S-1 · filed 2026-08-18
-$465.04K
derived: sum of 3 quarters · filed 2026-08-18
-$542.57K
derived: sum of 4 quarters · filed 2026-08-18
2025-03-31-$237.75K
S-4/A · filed 2026-06-11
-$317.52K
derived: sum of 2 quarters · filed 2026-08-18
-$395.04K
derived: sum of 3 quarters · filed 2026-08-18
-$591.37K
derived: sum of 4 quarters · filed 2026-08-18
2024-12-31-$79.77K
derived: S-1 9 month − 10-Q 6 month · filed 2026-08-18
-$157.30K
derived: sum of 2 quarters · filed 2026-08-18
-$353.62K
S-1 · filed 2026-08-18
2024-09-30-$77.53K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13
-$273.85K
10-Q · filed 2025-11-13
2024-06-30-$196.33K
10-Q · filed 2025-08-13
2024-03-31$0.00
10-Q · filed 2025-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
EXAGEN INC. (XGN)United States$0.212B-5.95
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45